BUTRANS (buprenorphine) by Purdue Pharma is partial opioid agonists [moa]. First approved in 2010.
Drug data last refreshed 13h ago · AI intelligence enriched 2d ago
BUTRANS is a transdermal extended-release film formulation of buprenorphine, a partial opioid agonist approved in 2010 for chronic pain management. It delivers consistent opioid analgesia through the skin over extended periods, reducing breakthrough pain and the need for frequent dosing. The partial agonist mechanism provides a ceiling effect on respiratory depression compared to full opioids, making it a safer opioid option for chronic pain patients.
Product is approaching loss of exclusivity with moderate Medicare Part D spending; expect transition from growth-focused to defensive and efficiency-driven commercial activities.
Partial Opioid Agonists
Partial Opioid Agonist
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Acceptability and Feasibility of Extended-Release Subcutaneous Buprenorphine on a Mobile Pharmacy Clinic
Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder
A Study to Test Whether BI 1356225 Improves Impulsive Behavior in People With Opioid Use Disorder Who Are Taking Buprenorphine
Drug-drug Interaction Study of Bemnifosbuvir/Ruzasvir (BEM/RZR) and Buprenorphine/Naloxone or Methadone
An Exploratory Clinical Study of a Low-dose Buprenorphine Patch for the Treatment of Autism Spectrum Disorders
Worked on BUTRANS at Purdue Pharma? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on BUTRANS offers exposure to mature commercial execution, specialty pain management, and regulated opioid marketing in a constrained environment. However, the approaching LOE and zero linked job postings signal limited career development momentum; professionals should expect focus on retention and efficiency rather than expansion.